Samba Signs CDMO Agreement with Enzolytics, Developer of COVID-19 Antibody Therapeutics

Incheon Songdo Samsung Biologics Plant 3 Exterior (Photo by Samsung Biologics)

[Asia Economy Reporter Chunhee Lee] Samsung Biologics announced on the 8th that it has signed a contract for contract development and manufacturing organization (CDMO) services with the U.S. antibody therapeutic developer Enzolytics.

Under this contract, Samsung Biologics will provide end-to-end CDMO services from cell line development to clinical material production and Investigational New Drug (IND) application support for Enzolytics' COVID-19 monoclonal antibody therapeutic and human immunodeficiency virus (HIV) monoclonal antibody therapeutic for acquired immunodeficiency syndrome (AIDS). Discussions will also be held for contracts related to other antibody therapeutics currently being developed by Enzolytics.

Enzolytics is developing antibody therapeutics targeting immutable sites within viruses based on an artificial intelligence (AI) platform, enabling response to variant viruses. Samsung Biologics will support Enzolytics' cell line development through its contract development and manufacturing (CDO) research and development (R&D) center in San Francisco, USA. Clinical material production will be carried out at the headquarters in Songdo, Incheon.

John Rim, CEO of Samsung Biologics, said, "We are confident that Enzolytics will successfully achieve its goals through the world's most competitive end-to-end CDMO services," adding, "We will do our best to accelerate new drug development and ensure that therapeutics are promptly supplied to patients worldwide based on high-quality services and expertise."

Gaurav Chandra, Chief Operating Officer (COO) of Enzolytics, also said, "We decided on this collaboration considering Samsung Biologics' extensive experience and expertise in the development, production, and manufacturing of monoclonal antibody therapeutics," adding, "We will ensure that patients receive treatment in a timely manner by shortening the clinical and development timelines for monoclonal antibody therapeutics."